Amarin Corp Plc (AMRN)

[dogn]

Texas Prior Authorization Program Clinical Criteria updated Aug 17, 2023

Drug/Drug Class: Omega-3 Fatty Acids

https://www.uhcprovider.com/en/resource-library/news/2023/tx-medicaid-prior-auth-certain-medications.html

https://paxpress.txpa.hidinc.com/lovazapdg.pdf

Revision Notes: Added GCNs for Icosapent Ethyl (33238, 42365)

Generic Vascepa requires prior authorization to confirm non-infringing use (for TG>500); Reduce-it indication authorizes brand Vascepa.

Publication History last page shows:
07/05/2022 Added [Reduce-it] criteria for Vascepa…
12/20/2022 Clarified criteria for Vascepa …
1/03/23 Renamed the guide to Omega-3 Fatty Acids (formerly Lovaza)
7/17/2023 Added GCNs for Icosapent Ethyl (33238, 42365)

Perhaps changes related to Healthnet settlement? Appears patients meeting Reduce-it CVD indication are indeed approved to receive brand Vascepa only.

UnitedHealthcare is in partnership with Health Net at least in some states https://www.unitedhealthgroup.com/newsroom/posts/2022/2022-03-15-partnering-with-healthnet-expanding-access-384928.html

https://www.healthnet.com/static/provider/unprotected/pdfs/national/close_announcement_provider_FAQs.pdf

https://www.uhccommunityplan.com/missouri

dogn